Merck Provides New Results for VERQUVO® (vericiguat) in Patients with Chronic Heart Failure and Reduced Ejection Fraction
(NYSE:MRK) RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Provides New Results for Vericiguat in Patients with Chronic Heart Failure and Reduced Ejection Fraction. Results presented at ESC 2025
Related Questions
How will the new VERQUVO® trial results affect Merck's stock price in the short term?
What are the timelines for regulatory approval and market launch of VERQUVO® based on these results?
How does VERQUVO® compare to existing heart‑failure therapies and competitors' pipelines in terms of efficacy and market potential?